RAThe Effect of TNF-alpha Blocking Therapy on Lipid Levels in Rheumatoid Arthritis: A Meta-Analysis
Section snippets
Search and Selection-Strategy
A systematic search of the literature published until May 2010 was conducted in MEDLINE, Cochrane library, and EMBASE to identify all articles investigating lipid profiles in RA patients treated with TNF-alpha blocking agents. Search terms were used in every possible spelling, as synonyms, acronyms, key- or text words. The following key words were used in all fields: (“arthritis, rheumatoid”) AND (“cholesterol” OR “HDL” OR “LDL” OR “triglycerides” OR “atherogenic index” OR “apolipoprotein A”)
Included Studies and Population Characteristics
For the present meta-analyses 15 studies with data on TC in 766 patients and 14 studies with data on HDLc in 736 patients were available that met our inclusion criteria (12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26) (Table 1). All included studies used data of patients initiating TNF-alpha blocking therapy for the first time and were thus TNF-alpha blocking agent-naïve at baseline. Five studies had a study population of more than 50 individuals (14, 15, 19, 25, 26). Mean follow-up
Discussion
To date, some systematic reviews have focused on the effect of TNF-alpha blocking therapy on lipid levels in RA, yet none have produced a summary estimate of the changes in lipid levels following TNF-alpha blocking therapy (2, 31, 32, 33, 34). The present study therefore is the first to describe a summary estimate of 10% increase for TC and 7% increase for HDLc within a period of 6 months. In addition, results from available studies were more consistent than originally perceived, as a rise in
References (45)
- et al.
Effect of anti TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterol
Atherosclerosis
(2004) - et al.
Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis
Clin Chim Acta
(2006) - et al.
Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis
Joint Bone Spine
(2008) - et al.
Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews
J Clin Epidemiol
(2005) - et al.
Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis
J Clin Epidemiol
(2001) - et al.
Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment
Semin Arthritis Rheum
(2009) - et al.
The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia
J Autoimmun
(2007) - et al.
The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk
J Lipid Res
(2007) - et al.
Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies
Arthritis Rheum
(2008) - et al.
Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions
Ann Rheum Dis
(2009)
Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis
Circulation
Total cholesterol and LDL levels decrease before rheumatoid arthritis
Ann Rheum Dis
Lipid profiles in untreated patients with rheumatoid arthritis
J Rheumatol
Lipid profiles among US elderly with untreated rheumatoid arthritis—the Third National Health and Nutrition Examination Survey
J Rheumatol
Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register
Arthritis Rheum
All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists
Ann Rheum Dis
Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis
J Rheumatol
Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis
Ann Rheum Dis
Role for TNF in atherosclerosis?Lessons from autoimmune disease
Nat Rev Cardiol
Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis
Ann Rheum Dis
Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis
J Rheumatol
Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis
Ann NY Acad Sci
Cited by (0)
The authors declare that there are no competing interests. However, the Departments of Rheumatology of the VU Medical Centre and Jan van Breemen Research Institute have both received funds for educational and research purposes from Pfizer, Abbott, UCB, MSD, BMS, and Roche. However, they had no involvement in the study design, in the collection, analysis, and interpretation of the data, in the writing of the report, or in the decision to submit the paper for publication.
NS has received research and lecture grants from Roche; MN has received speaking grants, ad-hoc consultancy grants, and congress support from Pfizer, Abbott, UCB, MSD, BMS, and Roche.